ABSTRACT
INTRODUCTION
As the number one cause of mortality worldwide [1] , there is no doubt that hypertension is a major public health concern in today's society. Current statistics report that globally almost 1 billion individuals have high blood pressure (BP) [2, 3] , and by 2025, the prevalence of hypertension is expected to increase by about 60% to 1.56 billion [2] . Importantly, almost threequarters of this hypertensive population will reside in economically developing countries [2] .
Hypertension is one of the most common and treatable risk factors for cardiovascular (CV) morbidity and mortality [3] . It is also often clustered with other CV risk factors such as diabetes, obesity, and metabolic syndrome, placing patients at even greater risk of CV disease [4, 5] . Data from 2001 showed that nonoptimal BP, defined as systolic BP (SBP) ≥115 mmHg, was responsible for 54% of all strokes and 47% of all cases of ischemic heart disease [6] . Moreover, approximately 80% of the CV disease burden attributable to hypertension occurred in low-and middle-income countries, including Asia and the Middle East [6] .
Despite evidence showing that effective BP lowering can reduce the risk of CV events [7] , and the availability of numerous efficacious antihypertensive agents, control of high BP to guideline-recommended targets remains a global challenge [8, 9] . Indeed, in parts of Asia, BP control rates in patients receiving antihypertensive treatment are as low as 20% [10] , a reflection of what is being seen elsewhere in the world. There are numerous reasons for failure to achieve BP targets in patients receiving antihypertensive treatment, including noncompliance/nonpersistence with therapy, suboptimal antihypertensive treatment efficacy, and poorly tolerated regimens [11] .
Aliskiren is a first-in-class direct renin inhibitor, which acts at the rate-limiting step of the renin-angiotensin-aldosterone system (RAAS) and reduces plasma renin activity, angiotensin I, angiotensin II, and aldosterone [12, 13] hypertension [14] , metabolic comorbidities, or obesity [15, 16] , and the elderly [17] .
As only limited published data are available on the real-world effectiveness and safety of aliskiren [18] [19] [20] , particularly in regions such as Asia and the Middle East, the present study was conducted to characterize and assess the effectiveness, safety and tolerability of aliskiren and the single-pill combination (SPC) of aliskiren HCT as antihypertensive therapy under dailylife conditions during a planned observation and treatment period of at least 26 weeks in a multiethnic population. 
MATERIALS AND METHODS

Study Design and Patient Population
RESULTS
Patient Disposition
Of the 5,366 patients enrolled in the study, evaluable data were available for 4,829 patients, all of whom were included in the FAS. Of Table 2 . The mean age was 51.4 years and the majority of patients were male (65.9%) and 
Full analysis set HCT hydrochlorothiazide 
Safety and Tolerability
AEs occurred in a total of 101 (2.1%) patients (Table 4 ). The most common AEs included headache, onset of diabetes mellitus, abdominal discomfort, and dizziness (Table 4 . BP blood pressure, ISH isolated systolic hypertension, msDBP mean sitting diastolic blood pressure, msSBP mean sitting systolic blood pressure. *P < 0.001 for msSBP and msDBP versus baseline BP for all subgroups Pakistan [23] and the United Arab Emirates [24] where under-diagnosis and under-treatment rates pose serious challenges. The present study also showed that during the observation and treatment period of Consequently, despite the benign safety data observed in the present study, we would still caution against the use of aliskiren in a diabetic population as add-on to another RAAS inhibitor, in line with the updated prescribing information available from the study sponsor.
An additional element of the present study was the investigator assessment of treatment effectiveness, tolerability, and compliance.
Overall, the effectiveness and tolerability of aliskiren and aliskiren HCT was rated as "good" or "very good" for almost all patients (effectiveness:
89.3%; tolerability: 93.7%). Treatment compliance was also judged to be "good" or "very good" for more than 90% of patients; a reflection of the proportion of patients (95%) who continued on treatment after the study.
Accepting that heightened compliance may partly be a consequence of patient involvement in a study, these findings are noteworthy nonetheless given that noncompliance with treatment is a major obstacle to achieving BP goal worldwide, including South and East Asia where challenges surrounding economic burden and access to treatment dominate [32, 33] . 
